Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 5/20 | 0.54 |
| ▸ | DRD3 | P35462 | 4/20 | 0.54 |
| ▸ | DRD2 | P14416 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 6/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | RORC | P51449 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17064137 | 0.88 | MEN1 (0.62) | HTR6DRD3DRD2MEN1KMT2A | |
| SCHEMBL17070599 | 0.88 | MEN1 (0.62) | HTR6DRD3DRD2MEN1KMT2A | |
| SCHEMBL17064153 | 0.88 | HTR6 (0.57) | HTR6DRD3DRD2MEN1KMT2A | |
| SCHEMBL13302143 | 0.88 | MAPT (0.54) | HTR6DRD3DRD2MEN1KMT2A | |
| SCHEMBL12053364 | 0.84 | MEN1 (0.73) | MEN1KMT2AALDH1A1ATMMAPT | |
| SCHEMBL10192216 | 0.82 | NPC1 (0.48) | MEN1KMT2APOLBALDH1A1PKM | |
| SCHEMBL13495466 | 0.81 | MEN1 (0.47) | HTR6DRD3DRD2MEN1KMT2A | |
| SCHEMBL13495474 | 0.81 | HTR6 (0.49) | HTR6DRD3DRD2MEN1KMT2A | |
| SCHEMBL13495476 | 0.81 | PDE4A (0.47) | HTR6DRD3DRD2MEN1KMT2A | |
| SCHEMBL12333491 | 0.81 | ALDH1A1 (0.46) | HTR6DRD3DRD2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9951073-B2 | Compounds and compositions for treating chemical warfare agent-induced injuries | HYDRA BIOSCIENCES, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| EP-3184527-A1 | 2,6-DIOXO,-2,3-DIHYDRO-1H-PURINE COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO THE ACTIVITY OF THE TRPA1 CHANNEL | Hydra Biosciences, Inc. (US) | 2017-06-28 | — | — | EP | disclosed |
| US-20140031334-A1 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-01-30 | — | — | US | disclosed |
| US-20140031334-A1 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-01-30 | — | — | US | disclosed |
| US-20130303521-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | HYDRA BIOSCIENCES, INC (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130303521-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | HYDRA BIOSCIENCES, INC (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130059869-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | HYDRA BIOSCIENCES, INC. | 2013-03-07 | — | — | US | disclosed |
| US-20130059869-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | HYDRA BIOSCIENCES, INC. | 2013-03-07 | — | — | US | disclosed |
| US-8163761-B2 | Methods and compositions for treating disorders | HYDRA BIOSCIENCES, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20120046305-A1 | METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY DISORDERS | ELI LILLY AND COMPANY | 2012-02-23 | — | — | US | disclosed |
| US-20120028920-A1 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. | 2012-02-02 | — | — | US | disclosed |
| US-8071600-B2 | Derivatives of 4-piperazin-1-yl-4-benzo[B]thiophene suitable for the treatment of CNS disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-12-06 | — | — | US | disclosed |
| EP-2287161-A1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders | Otsuka Pharmaceutical Co., Limited (JP) | 2011-02-23 | — | — | EP | disclosed |
| US-20090143377-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | ELI LILLY AND COMPANY | 2009-06-04 | — | — | US | disclosed |
| WO-2007026959-A2 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZ0 [B] THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028920-A1 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | GRIN2C, GRIN2B, PMP22 | HTR6 172/4885DRD3 161/4885DRD2 139/4885 |
| US-20140031334-A1 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | GRIN2C, GRIN2B, PMP22 | HTR6 172/4885DRD3 161/4885DRD2 139/4885 |
| US-20090143377-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | TRPA1, TRPV1, TRPV3 | HTR6 105/4885DRD3 2829/4885DRD2 2791/4885 |
| US-20120046305-A1 | METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY DISORDERS | TRPA1, TRPV1, TRPV3 | HTR6 446/4885DRD3 2472/4885DRD2 2269/4885 |
| US-20130303521-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | ELANE, CASP3, MMP8 | HTR6 4362/4885DRD3 1876/4885DRD2 2429/4885 |
| US-20130059869-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | TRPA1, TRPV1, TRPV3 | HTR6 105/4885DRD3 2829/4885DRD2 2791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.